Development and Validation of Clinically Useful Gene Signatures

September 3, 2010

IDDI organized its second free live webinar on DEVELOPMENT AND VALIDATION OF CLINICALLY USEFUL GENE SIGNATURES.

  • This webinar reviewed statistical issues in the development and validation of gene signatures for breast cancer. Using three recently developed signatures (MammaPrint®, Oncotype DX® and MapQuant DxTM), the speakers discussed the role of gene selection, classification methods and cluster analysis in signature development, as well as the need for internal and external validation of the signatures.
  • The speakers were Dr Marc Buyse, Chairman IDDI and Dr. Stefan Michiels, Breast Cancer Translational Unit, Institut Jules Bordet and Senior Biostatistical Consultant IDDI.

VIEW THE RECORDING OF THE WEBINAR HERE 

TO ACCESS THE PRESENTATION OF THIS ON-DEMAND WEBINAR, PLEASE FILL IN THE FORM BELOW

 

Presentation of the Webinar: Development and Validation of Clinically Useful Gene Signature

To access the presentation of this on-demand webinar, please fill out this form.

By submitting this form, you agree to receiving commercial electronic messages such as e-mails from IDDI. For more info, please visit our Privacy Policy. You can unsubscribe at any time by clicking the 'unsubscribe' button at the foot of any e-mail communication from IDDI.

I authorize IDDI to use my data to contact me for commercial purposes. More information
Powered by Atypic ®

IDDI